Selective tau seeding assays and isoform-specific antibodies define neuroanatomic distribution of progressive supranuclear palsy pathology arising in Alzheimer's disease.
Selective tau seeding assays and isoform-specific antibodies define neuroanatomic distribution of progressive supranuclear palsy pathology arising in Alzheimer's disease.
复制标题
DOI:
10.1007/s00401-022-02480-x
复制
发表时间:
2022-10
影响因子:
12.7
通讯作者:
中科院分区:
文献类型:
--
作者:
Incipient progressive supranuclear palsy (PSP) pathology in the setting of Alzheimer’s disease neuropathologic change (ADNC) has only rarely been reported (see Supplemental Table 1 for key prior works)[1]. These works suggest that the stereotyped neuroanatomic distribution of AD-related 3R/4R tauopathy and PSP-related 4R tauopathy are preserved in this setting; however, this has not been rigorously examined. Recently, isoform-specific tau antibodies (RD3, RD4, and AD-specific GT38) and isoform-selective tau seeding assays (3R/4R and 4R real-time quaking-induced conversion [RT-QuIC]) have been developed by us and others (methods and references in Supplement) that we hypothesized should delineate the neuroanatomic localization of co-occurring 3R/4R and 4R-tau pathology. We tested this hypothesis in five cases of high ADNC with incidental PSP (“ADNC+ PSPi”) pathology and found, first, that neuroanatomic distributions of 4R PSP and 3R/4R AD pathology are conserved in ADNC+ PSPi and, second, that RT-QuIC can robustly distinguish the neuroanatomic distribution of 3R/4R versus 4R pathology in cases with mixed tau pathology, suggesting its utility as a tool to interrogate pathophysiology. We reviewed 1296 autopsy cases with intermediate or high ADNC and identified 5 cases (0.3%) with incidental co-occurring PSP pathology (Table 1 for additional clinical and pathologic information). Age of onset was 72±3.8 years and disease duration was 11±2.1 years (mean±SD). Two cases had mild parkinsonism; one had gait disorder 5 years after symptom onset. No cases met NINDS-SPSP or MDS criteria for possible or probable PSP [2]. Case 3 had extensive aging-related tau astrogliopathy (ARTAG, 4R tauopathy) throughout the brain.Immunohistochemistry and immunofluorescence for phospho-tau (AT8), 3R-tau (RD3), 4R-tau (RD4), and AD-specific tau (GT38) was performed on pons, midbrain, hippocampus, basal ganglia, temporal cortex, midfrontal cortex, and occipital cortex (see Supplement for methods). In ADNC+ PSPi, we could distinguish AD pathology from PSP pathology by staining characteristics and morphology of inclusions: all pathological phospho-tau inclusions stained with AT8; AD neurofibrillary tangles (NFTs) but not PSP pathology stained with GT38 and RD3; PSP pathology stained with RD4 but not GT38. Consistent with the neuroanatomic distributions of each pathology in isolation, GT38-positive NFTs were abundant in midfrontal cortex and hippocampus, while RD4-positive astrocytes and oligodendroglia were prominent in midfrontal white matter and basal ganglia (Fig. 1 a, S1). Semi-quantitative regional scoring demonstrated similar neuroanatomic distribution of AD versus PSP pathology in the five cases (Fig. 1 b and Supplemental Results).